A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com..
INTRODUCTION: A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.
METHODS: Healthy adults (n=180), ages 19-50 years, were enrolled into this partially-blinded, randomized, multi-center Phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with two different boost intervals (21 versus 120 days) and two dosages (3.75 or 15 μg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition (HAI) and neutralizing antibody titers were assessed.
RESULTS: Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest HAI GMT (95%CI) observed against the 2017 A(H7N9) strain was 133.4 (83.6, 212.6) among participants who received homologous, adjuvanted 3.75 ug+AS03/2017 doses with delayed boost interval.
CONCLUSIONS: Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. (NCT03589807).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2024) vom: 27. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rostad, Christina A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2013 H7N9 |
|---|
| Anmerkungen: |
Date Revised 27.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03589807 Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciae173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370267966 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370267966 | ||
| 003 | DE-627 | ||
| 005 | 20240329001616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciae173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM370267966 | ||
| 035 | |a (NLM)38537255 | ||
| 035 | |a (PII)ciae173 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rostad, Christina A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03589807 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprintsoup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. | ||
| 520 | |a INTRODUCTION: A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs | ||
| 520 | |a METHODS: Healthy adults (n=180), ages 19-50 years, were enrolled into this partially-blinded, randomized, multi-center Phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with two different boost intervals (21 versus 120 days) and two dosages (3.75 or 15 μg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition (HAI) and neutralizing antibody titers were assessed | ||
| 520 | |a RESULTS: Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest HAI GMT (95%CI) observed against the 2017 A(H7N9) strain was 133.4 (83.6, 212.6) among participants who received homologous, adjuvanted 3.75 ug+AS03/2017 doses with delayed boost interval | ||
| 520 | |a CONCLUSIONS: Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. (NCT03589807) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 2013 H7N9 | |
| 650 | 4 | |a 2017 H7N9 | |
| 650 | 4 | |a Avian Influenza | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a boost | |
| 700 | 1 | |a Atmar, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Emmanuel B |e verfasserin |4 aut | |
| 700 | 1 | |a Frey, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Meier, Jeffery L |e verfasserin |4 aut | |
| 700 | 1 | |a Sherman, Amy C |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Lilin |e verfasserin |4 aut | |
| 700 | 1 | |a Tsong, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Carol M |e verfasserin |4 aut | |
| 700 | 1 | |a Raabe, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a El Sahly, Hana M |e verfasserin |4 aut | |
| 700 | 1 | |a Keitel, Wendy A |e verfasserin |4 aut | |
| 700 | 1 | |a Whitaker, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Schmader, Kenneth E |e verfasserin |4 aut | |
| 700 | 1 | |a Swamy, Geeta K |e verfasserin |4 aut | |
| 700 | 1 | |a Abate, Getahun |e verfasserin |4 aut | |
| 700 | 1 | |a Winokur, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Buchanan, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Cross, Kaitlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Wegel, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yongxian |e verfasserin |4 aut | |
| 700 | 1 | |a Yildirim, Inci |e verfasserin |4 aut | |
| 700 | 1 | |a Kamidani, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Rouphael, Nadine |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Paul C |e verfasserin |4 aut | |
| 700 | 1 | |a Mulligan, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Evan J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2024) vom: 27. März |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:27 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciae173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 27 |c 03 | ||